NCT01983735 - Efficacy and Safety of TELMINUVO to Stage 2 Hypertension | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Hypertension

Interventions

DRUG

TELMINUVO Tab. (80/2.5mg)

"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."

DRUG

TELMINUVO Tab. (80/5mg)

"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."

DRUG

S-amlodipine 2.5mg

"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."

DRUG

S-amlodipine 5mg

"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."

Trial Locations (1)

The catholic university of Korea Seoul St. Mary's hospital, Seoul